KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $2.4 billion.

  • Eli Lilly's Accumulated Expenses rose 1341.93% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 billion, marking a year-over-year increase of 1341.93%. This contributed to the annual value of $2.4 billion for FY2025, which is 1341.93% up from last year.
  • Per Eli Lilly's latest filing, its Accumulated Expenses stood at $2.4 billion for Q4 2025, which was up 1341.93% from $2.0 billion recorded in Q3 2025.
  • Eli Lilly's Accumulated Expenses' 5-year high stood at $2.4 billion during Q4 2025, with a 5-year trough of $649.9 million in Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $1.0 billion (2022), whereas its average is $1.2 billion.
  • As far as peak fluctuations go, Eli Lilly's Accumulated Expenses tumbled by 392.1% in 2021, and later soared by 5572.75% in 2023.
  • Over the past 5 years, Eli Lilly's Accumulated Expenses (Quarter) stood at $958.1 million in 2021, then grew by 10.61% to $1.1 billion in 2022, then soared by 55.73% to $1.7 billion in 2023, then grew by 26.88% to $2.1 billion in 2024, then grew by 13.42% to $2.4 billion in 2025.
  • Its Accumulated Expenses stands at $2.4 billion for Q4 2025, versus $2.0 billion for Q3 2025 and $1.3 billion for Q2 2025.